愛(ài)爾蘭Warner Chilcott www.wcrx.com
Warner Chilcott的產(chǎn)品包括口服避孕藥、護(hù)膚產(chǎn)品與激素治療乳，以生產(chǎn)和銷(xiāo)售系列女性激素替代療法藥物聞名，公司2008年?duì)I收為9.38億美元。
愛(ài)爾蘭Warner Chilcott
We are a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceutical market. We are a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. We have established strong franchises in women's healthcare and dermatology through our marketing techniques and specialty sales forces. We believe that our proven product development capabilities, coupled with our ability to execute acquisitions and in-licensing transactions and develop partnerships will enable us to sustain and grow our business.

We have assembled a diversified portfolio of branded products through a combination of acquisitions, internal development and in-licensing arrangements. Multiple products make up our existing revenue base and several products provide the opportunities for future growth.

Our internal product development efforts focus on new products as well as improvements to our existing women's healthcare and dermatology products. We often perform our own formulation work, which is conducted in-house by our talented colleagues in Larne, Northern Ireland. Our Fajardo, Puerto Rico facility can produce pilot quantities of product for clinical trials as well as scale up for commercial production. Our clinical development team designs and manages the clinical trial process. Our internal product development efforts are supported by our regulatory team, which has an impressive track record of effectively navigating the regulatory approval process. With the support of each one of these teams, we continue to work to develop new and next generation products. These internal development capabilities enable us to effectively and efficiently manage our investment in product research and development.

In addition to our internal product development efforts, we have selectively pursued strategic product in-licensing and acquisition opportunities that have enabled us to add new products to our portfolio, such as our relationship with LEO Pharma.

We have two manufacturing facilities, one in Fajardo, Puerto Rico and the other in Larne, Northern Ireland. Our Fajardo facility currently manufactures the majority of the women's healthcare products that we promote. These facilities give us a "speed to market" advantage and enable us to maintain a reliable source of supply.

An enduring strength of our company lies in our management team. The members of our senior team have extensive experience in the pharmaceutical industry. The quality of our team and the benefits of having worked together for many years, are clearly demonstrated in the growth of our company over the last decade. Over the last several years we've added talent to our team to ensure that we have the leadership in place to support future growth.